1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
2.
|
Wieser M, Sauerland S, Arnold D, Schmiegel
W and Reinacher-Schick A: Peri-operative chemotherapy for the
treatment of resectable liver metastases from colorectal cancer: A
systematic review and meta-analysis of randomized trials. BMC
Cancer. 10:3092010. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Murata S, Moriya Y, Akasu T, Fujita S and
Sugihara K: Resection of both hepatic and pulmonary metastases in
patients with colorectal carcinoma. Cancer. 83:1086–1093. 1998.
View Article : Google Scholar : PubMed/NCBI
|
4.
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
5.
|
Havlik R, Jiao LR, Nicholls J, Jensen SL
and Habib NA: Gene therapy for liver metastases. Semin Oncol.
29:202–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong
Y and Bertino JR: Molecular therapies for colorectal cancer
metastatic to the liver. Mol Ther. 5:492–500. 2002. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Ruan DT and Warren RS: Liver-directed
therapies in colorectal cancer. Semin Oncol. 32:85–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
8.
|
Stojdl DF, Lichty B, Knowles S, et al:
Exploiting tumor-specific defects in the interferon pathway with a
previously unknown oncolytic virus. Nat Med. 6:821–825. 2000.
View Article : Google Scholar : PubMed/NCBI
|
9.
|
Balachandran S and Barber GN: Vesicular
stomatitis virus (VSV) therapy of tumors. IUBMB Life. 50:135–138.
2000. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Balachandran S, Porosnicu M and Barber GN:
Oncolytic activity of vesicular stomatitis virus is effective
against tumors exhibiting aberrant p53, Ras, or myc function and
involves the induction of apoptosis. J Virol. 75:3474–3479. 2001.
View Article : Google Scholar : PubMed/NCBI
|
11.
|
Balachandran S and Barber GN: Defective
translational control facilitates vesicular stomatitis virus
oncolysis. Cancer Cell. 5:51–65. 2004. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Shinozaki K, Ebert O and Woo SL:
Eradication of advanced hepatocellular carcinoma in rats via
repeated hepatic arterial infusions of recombinant VSV. Hepatology.
41:196–203. 2005. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Inoue Y, Kashima Y, Aizawa K and
Hatakeyama K: A new rat colon cancer cell line metastasizes
spontaneously: biologic characteristics and chemotherapeutic
response. Jpn J Cancer Res. 82:90–97. 1991. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Ebert O, Shinozaki K, Kournioti C, Park
MS, Garcia-Sastre A and Woo SL: Syncytia induction enhances the
oncolytic potential of vesicular stomatitis virus in virotherapy
for cancer. Cancer Res. 64:3265–3270. 2004. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Shinozaki K, Ebert O, Kournioti C, Tai YS
and Woo SL: Oncolysis of multifocal hepatocellular carcinoma in the
rat liver by hepatic artery infusion of vesicular stomatitis virus.
Mol Ther. 9:368–376. 2004. View Article : Google Scholar
|
16.
|
Fernandes-Alnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and
mammalian interleukin-1 beta-converting enzyme. J Biol Chem.
269:30761–30764. 1994.PubMed/NCBI
|
17.
|
Kopecky SA, Willingham MC and Lyles DS:
Matrix protein and another viral component contribute to induction
of apoptosis in cells infected with vesicular stomatitis virus. J
Virol. 75:12169–12181. 2001. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Bell JC, Lichty B and Stojdl D: Getting
oncolytic virus therapies off the ground. Cancer Cell. 4:7–11.
2003. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Giedlin MA, Cook DN and Dubensky TW Jr:
Vesicular stomatitis virus: an exciting new therapeutic oncolytic
virus candidate for cancer or just another chapter from Field’s
Virology? Cancer Cell. 4:241–243. 2003.
|
20.
|
Lichty BD, Power AT, Stojdl DF and Bell
JC: Vesicular stomatitis virus: re-inventing the bullet. Trends Mol
Med. 10:210–216. 2004. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Barber GN: Vesicular stomatitis virus as
an oncolytic vector. Viral Immunol. 17:516–527. 2004. View Article : Google Scholar : PubMed/NCBI
|
22.
|
McCormick F: Future prospects for
oncolytic therapy. Oncogene. 24:7817–7819. 2005. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Everts B and van der Poel HG:
Replication-selective oncolytic viruses in the treatment of cancer.
Cancer Gene Ther. 12:141–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Shinozaki K, Ebert O and Woo SL: Treatment
of multi-focal colorectal carcinoma metastatic to the liver of
immune-competent and syngeneic rats by hepatic artery infusion of
oncolytic vesicular stomatitis virus. Int J Cancer. 114:659–664.
2005. View Article : Google Scholar
|
25.
|
Parato KA, Senger D, Forsyth PA and Bell
JC: Recent progress in the battle between oncolytic viruses and
tumours. Nat Rev Cancer. 5:965–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Mills BJ and Cooper NR:
Antibody-independent neutralization of vesicular stomatitis virus
by human complement. I. Complement requirements. J Immunol.
121:1549–1557. 1978.PubMed/NCBI
|